Norris Medicines Reports Q4 Profit, Reduced Annual Loss

Quarter ended March 31, 2026: Profit of ₹0.0506 crore (₹5.06 lakh)
Year ended March 31, 2026: Loss of ₹0.2806 crore (₹28.06 lakh)

Reader Takeaway: Quarterly profit turnaround and reduced annual loss offset by persistent negative equity.

What just happened

Norris Medicines Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a profit of ₹0.0506 crore (₹5.06 lakh) for the fourth quarter, a significant improvement from the loss of ₹0.2285 crore (₹22.85 lakh) in the same period last year. For the full fiscal year 2025-26, the company registered a net loss of ₹0.2806 crore (₹28.06 lakh), which is a substantial reduction from the ₹1.2375 crore (₹123.75 lakh) loss reported in the previous fiscal year.

Why this matters

The turnaround in quarterly performance suggests a potential improvement in operational profitability. The narrowing of the annual loss indicates the company is moving towards greater financial stability, which could be viewed positively by investors. However, the persistent negative equity remains a significant concern, highlighting accumulated losses.

The backstory

Norris Medicines has been focused on improving its financial performance over the last couple of fiscal years. While the company has faced losses, recent periods show efforts to control costs and enhance revenue. The appointment of internal auditors is a step towards strengthening financial oversight.

What changes now

Investors will be looking for the company to sustain its quarterly profitability and continue reducing its annual losses. The focus will also be on how management addresses the issue of negative equity. The appointment of M/s. Dhiren Y Parikh & Co. as internal auditors for FY 2026-2027 signals a commitment to improving internal controls.

Risks to watch

The primary risk remains the company's negative equity of ₹-15.148 crore as of March 31, 2026. This indicates that the company's liabilities exceed its assets, suggesting financial distress and potential solvency issues if not addressed.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

Quarterly Revenue:

• FY26 Q4: ₹1.4084 crore
• FY25 Q4: ₹2.7209 crore

Annual Revenue:

• FY26: ₹8.1320 crore
• FY25: ₹5.8202 crore

Annual Profit/Loss:

• FY26: ₹-0.2806 crore
• FY25: ₹-1.2375 crore

Balance Sheet (as of March 31, 2026):

• Total Assets: ₹12.8894 crore
• Total Equity: ₹-15.148 crore

What to track next

Investors should monitor the company's future quarterly results for sustained profitability and revenue growth. The progress in reducing the overall annual loss and any steps taken to improve the equity position will be crucial.